Previous close | 128.87 |
Open | 129.50 |
Bid | 128.25 x 800 |
Ask | 131.88 x 900 |
Day's range | 128.71 - 131.10 |
52-week range | 119.59 - 148.62 |
Volume | |
Avg. volume | 1,045,526 |
Market cap | 14.509B |
Beta (5Y monthly) | 0.89 |
PE ratio (TTM) | 17.52 |
EPS (TTM) | 7.48 |
Earnings date | 23 Apr 2024 |
Forward dividend & yield | 3.00 (2.29%) |
Ex-dividend date | 05 Apr 2024 |
1y target est | 141.71 |
A blood test that analyzes levels of amyloid proteins by highly sensitive mass spectrometry could help physicians establish that Alzheimer's disease (AD) is likely not the cause of patients' mild cognitive impairment, finds a new study published in Frontiers in Neurology by researchers from Quest Diagnostics (NYSE: DGX), the University of Florida and Mount Sinai Medical Center in Miami Beach.
Labcorp's (LH) pTau217 test is a pivotal blood biomarker intended to aid in the diagnosis of Alzheimer's disease.
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2024 financial results on Tuesday, April 23, 2024, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.